2021
DOI: 10.1016/j.jaad.2020.12.034
|View full text |Cite
|
Sign up to set email alerts
|

The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
21
2
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(32 citation statements)
references
References 3 publications
7
21
2
2
Order By: Relevance
“…The commencement of new protocols was because melanoma patients attending the daycare in the final third of 2020 were with more extensive disease and requiring a change of treatment regime. A similar trend was noted in the University of Pennsylvania [ 13 ]. The physicians there reported a more advanced malignant melanoma presentation in the COVID-19 era.…”
Section: Discussionsupporting
confidence: 85%
“…The commencement of new protocols was because melanoma patients attending the daycare in the final third of 2020 were with more extensive disease and requiring a change of treatment regime. A similar trend was noted in the University of Pennsylvania [ 13 ]. The physicians there reported a more advanced malignant melanoma presentation in the COVID-19 era.…”
Section: Discussionsupporting
confidence: 85%
“… 15 102 For example, a recent US-based single-center study observed that patients diagnosed with melanoma during the COVID-19 pandemic exhibited significantly higher tumor depth, mitotic rates, satellitosis, and pT3/T4 tumors compared with those diagnosed in the pre COVID-19 setting. 103 In addition, a multicenter Italian study of 169 patients with advanced (stages III and IV) melanoma on ICI found 49 (29%) of these patients to experience a delay in their ICI treatment for a median of 4 weeks due to clinician’s concerns of frailty and increased risk of contracting COVID-19, while actual COVID-19 diagnoses of this entire cohort were ultimately found to be lower than the general population. 93 With no clear evidence suggesting that ICIs worsen the risk or course of a COVID-19 infection, many sources have concurred that patients with melanoma, particularly those of an advanced stage, be treated without hesitation via standard of care regimens including ICIs and targeted therapy pending individual serine–threonine protein kinase B-RAF (BRAF) mutational status.…”
Section: Melanoma-specific Clinical Considerations Regarding Sars-cov-2 and Ici Usementioning
confidence: 99%
“… 7 Other US authors reported no difference in the proportion of in situ and invasive tumours for the same time periods, although the Breslow thickness of invasive tumours was greater. 8 …”
Section: Reportmentioning
confidence: 99%